ArticleBrain communications2025
Effects of Parkinson's disease on survival in cancer survivors: a retrospective, multicentre cohort study in Japan.
Article in Brain communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aging populations and advances in medical care have contributed to an increase in the number of patients with Parkinson's disease and cancer survivors. However, the effects of Parkinson's disease on the survival of patients with cancer remain unclear. We aimed to investigate the effect of Parkinson's disease on the prognosis of patients with cancer. This retrospective multicentre cohort study used data from the Osaka Cancer Registry, which was linked to administrative data obtained between 2010 and 2015 in Japan. Patients with cancer who were followed up for 5 years after cancer diagnosis were categorized into Parkinson's disease and non- Parkinson's disease groups according to the presence of comorbid Parkinson's disease. We compared survival between the two groups using Kaplan-Meier analyses. Cox proportional-hazard models were used to assess the hazard ratio and 95% confidence interval of Parkinson's disease for all-cause mortality. Propensity-score matching was used to validate the analysis and address differences in clinical characteristics between the groups. The cohort included 118 999 patients with cancer and 1049 patients (0.9%) with comorbid Parkinson's disease. The patients in the Parkinson's disease group were older and had lower mobility than those in the non- Parkinson's disease group. Kaplan-Meier analysis revealed that the 5-year survival rate after cancer diagnosis was significantly worse in the Parkinson's disease group than in the non- Parkinson's disease group (54% versus 70%,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.